AZD2014, a dual mTOR inhibitor, attenuates cardiac hypertrophy in vitro and in vivo

Cardiac hypertrophy is one of the most common genetic heart disorders and considered a risk factor for cardiac morbidity and mortality. The mammalian target of rapamycin (mTOR) pathway plays a key regulatory function in cardiovascular physiology and pathology in hypertrophy. AZD2014 is a small-molec...

Descripción completa

Detalles Bibliográficos
Autores principales: Cha, Byung-Hyun, Jung, Minjin, Kim, Angela S., Lepak, Victoria C., Colson, Brett A., Bull, David A., Won, Youngwook
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529824/
https://www.ncbi.nlm.nih.gov/pubmed/34674743
http://dx.doi.org/10.1186/s13036-021-00276-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529824/
https://www.ncbi.nlm.nih.gov/pubmed/34674743
http://dx.doi.org/10.1186/s13036-021-00276-3

Ejemplares similares